GlyTech Overview
- Year Founded
-
2012
- Status
-
Acquired/Merged
- Employees
-
26
- Latest Deal Type
-
M&A
GlyTech General Information
Description
Developer of biopharmaceutical products designed to prepare purified and characterized human-type N-glycan. The company's products are natural glycoproteins and glycopeptides that are produced through glycoscience and chemical synthetic methods, enabling researchers to contribute to the advancement of human health and help them expand their glycoscience research fields, drug development options, and biotherapeutic analysis capabilities.
Contact Information
Website
www.glytech-inc.com(Operating Subsidiary)
Corporate Office
- 134, Chudoji Minamimachi
- KRP Number 1-2 Floor, Shimogyo-ku
- Kyoto, 600-8813
- Japan
Corporate Office
- 134, Chudoji Minamimachi
- KRP Number 1-2 Floor, Shimogyo-ku
- Kyoto, 600-8813
- Japan
GlyTech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 01-Aug-2024 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 01-Nov-2022 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 20-Oct-2021 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A) | 28-May-2018 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 31-Jan-2014 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 02-Apr-2012 | Completed | Startup |
GlyTech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C preferred | ||||||||
| B preferred | ||||||||
| A preferred | 1,099,910 | $3.74 | $3.74 | 1x | $3.74 | 21.12% |
GlyTech Patents
GlyTech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025234425-A1 | Novel peptide derivative and use thereof | Pending | 08-May-2024 | ||
| EP-4741410-A1 | Solubilization group for poorly water-soluble proteins | Pending | 06-Jul-2023 | ||
| WO-2025009591-A1 | Solubilization group for poorly water-soluble proteins | Inactive | 06-Jul-2023 | ||
| EP-4671376-A1 | Protein recognizing k-ras gene mutation cancer | Pending | 20-Feb-2023 | ||
| WO-2024176961-A1 | Protein recognizing k-ras gene mutation cancer | Inactive | 20-Feb-2023 | A61P35/00 |
GlyTech Signals
GlyTech Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Chushin Venture Capital | Corporate Venture Capital | Minority | ||
| DBJ Capital | Corporate Venture Capital | Minority | ||
| Fushimi Pharmaceutical | Corporation | Minority | ||
| J-Startup | Accelerator/Incubator | |||
| KH Neochem | Corporation | Minority |
GlyTech FAQs
-
When was GlyTech founded?
GlyTech was founded in 2012.
-
Where is GlyTech headquartered?
GlyTech is headquartered in Kyoto, Japan.
-
What is the size of GlyTech?
GlyTech has 26 total employees.
-
What industry is GlyTech in?
GlyTech’s primary industry is Biotechnology.
-
Is GlyTech a private or public company?
GlyTech is a Private company.
-
What is GlyTech’s current revenue?
The current revenue for GlyTech is .
-
How much funding has GlyTech raised over time?
GlyTech has raised $21.4M.
-
Who are GlyTech’s investors?
Chushin Venture Capital, DBJ Capital, Fushimi Pharmaceutical, J-Startup, and KH Neochem are 5 of 14 investors who have invested in GlyTech.
-
When was GlyTech acquired?
GlyTech was acquired on 01-Aug-2024.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process